PMID- 31907198
OWN - NLM
STAT- MEDLINE
DCOM- 20200708
LR  - 20200924
IS  - 1098-5522 (Electronic)
IS  - 0019-9567 (Print)
IS  - 0019-9567 (Linking)
VI  - 88
IP  - 4
DP  - 2020 Mar 23
TI  - Impact of Antibiotic-Resistant Bacteria on Immune Activation and Clostridioides 
      difficile Infection in the Mouse Intestine.
LID - 10.1128/IAI.00362-19 [doi]
LID - e00362-19
AB  - Antibiotic treatment of patients undergoing complex medical treatments can 
      deplete commensal bacterial strains from the intestinal microbiota, thereby 
      reducing colonization resistance against a wide range of antibiotic-resistant 
      pathogens. Loss of colonization resistance can lead to marked expansion of 
      vancomycin-resistant Enterococcus faecium (VRE), Klebsiella pneumoniae, and 
      Escherichia coli in the intestinal lumen, predisposing patients to bloodstream 
      invasion and sepsis. The impact of intestinal domination by these 
      antibiotic-resistant pathogens on mucosal immune defenses and epithelial and 
      mucin-mediated barrier integrity is unclear. We used a mouse model to study the 
      impact of intestinal domination by antibiotic-resistant bacterial species and 
      strains on the colonic mucosa. Intestinal colonization with K. pneumoniae, 
      Proteus mirabilis, or Enterobacter cloacae promoted greater recruitment of 
      neutrophils to the colonic mucosa. To test the hypothesis that the residual 
      microbiota influences the severity of colitis caused by infection with 
      Clostridioides difficile, we coinfected mice that were colonized with 
      ampicillin-resistant bacteria with a virulent strain of C. difficile and 
      monitored colonization and pathogenesis. Despite the compositional differences in 
      the gut microbiota, the severity of C. difficile infection (CDI) and mortality 
      did not differ significantly between mice colonized with different 
      ampicillin-resistant bacterial species. Our results suggest that the virulence 
      mechanisms enabling CDI and epithelial destruction outweigh the relatively minor 
      impact of less-virulent antibiotic-resistant intestinal bacteria on the outcome 
      of CDI.
CI  - Copyright (c) 2020 American Society for Microbiology.
FAU - Keith, James W
AU  - Keith JW
AD  - Immunology Program, Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, 
      Memorial Sloan Kettering Cancer Center, New York, New York, USA.
FAU - Dong, Qiwen
AU  - Dong Q
AD  - Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer 
      Center, New York, New York, USA.
FAU - Sorbara, Matthew T
AU  - Sorbara MT
AD  - Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer 
      Center, New York, New York, USA.
FAU - Becattini, Simone
AU  - Becattini S
AD  - Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer 
      Center, New York, New York, USA.
FAU - Sia, Jonathan K
AU  - Sia JK
AD  - Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer 
      Center, New York, New York, USA.
FAU - Gjonbalaj, Mergim
AU  - Gjonbalaj M
AD  - Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer 
      Center, New York, New York, USA.
FAU - Seok, Ruth
AU  - Seok R
AD  - Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer 
      Center, New York, New York, USA.
FAU - Leiner, Ingrid M
AU  - Leiner IM
AD  - Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer 
      Center, New York, New York, USA.
FAU - Littmann, Eric R
AU  - Littmann ER
AD  - Lucille Castori Center for Microbes, Inflammation and Cancer, Memorial Sloan 
      Kettering Cancer Center, New York, New York, USA.
FAU - Pamer, Eric G
AU  - Pamer EG
AD  - Immunology Program, Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, 
      Memorial Sloan Kettering Cancer Center, New York, New York, USA 
      egpamer@uchicago.edu.
AD  - Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer 
      Center, New York, New York, USA.
AD  - Lucille Castori Center for Microbes, Inflammation and Cancer, Memorial Sloan 
      Kettering Cancer Center, New York, New York, USA.
AD  - Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering 
      Cancer Center, New York, New York, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - R01 AI042135/AI/NIAID NIH HHS/United States
GR  - R01 AI095706/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20200323
PL  - United States
TA  - Infect Immun
JT  - Infection and immunity
JID - 0246127
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/*administration & dosage
MH  - Clostridium Infections/microbiology/*physiopathology
MH  - Colitis/microbiology/physiopathology
MH  - Disease Models, Animal
MH  - *Drug Resistance, Bacterial
MH  - Enterobacter cloacae/drug effects/*growth & development
MH  - Enterobacteriaceae Infections/*complications/drug therapy
MH  - Klebsiella pneumoniae/drug effects/*growth & development
MH  - Mice
MH  - Microbial Interactions
MH  - Proteus mirabilis/drug effects/*growth & development
MH  - Survival Analysis
PMC - PMC7093144
OTO - NOTNLM
OT  - immunology
EDAT- 2020/01/08 06:00
MHDA- 2020/07/09 06:00
PMCR- 2020/09/23
CRDT- 2020/01/08 06:00
PHST- 2019/05/08 00:00 [received]
PHST- 2019/12/20 00:00 [accepted]
PHST- 2020/01/08 06:00 [pubmed]
PHST- 2020/07/09 06:00 [medline]
PHST- 2020/01/08 06:00 [entrez]
PHST- 2020/09/23 00:00 [pmc-release]
AID - IAI.00362-19 [pii]
AID - 00362-19 [pii]
AID - 10.1128/IAI.00362-19 [doi]
PST - epublish
SO  - Infect Immun. 2020 Mar 23;88(4):e00362-19. doi: 10.1128/IAI.00362-19. Print 2020 
      Mar 23.